Trial reportMicrobiology spectrum2026
Diagnostic performance of upper airway sampling sites for SARS-CoV-2 and influenza testing.
Trial report in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05765838 (Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Early diagnosis of upper respiratory infections is essential to control infectious disease transmission within the community and to initiate relevant antiviral treatments. Nonetheless, variable sensitivities of sampling sites are often overlooked. We conducted a clinical trial at a COVID-19 outpatient test center, where healthcare workers collected nasopharyngeal, throat, nasal swabs, and saliva specimens. Each specimen was tested by RT-PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus A and B, and respiratory syncytial virus (RSV). Clinical information was collected at enrollment and again 13 months later using an online questionnaire. From 4 March to 31 March 2023, 253 individuals were enrolled. Data from 250 participants were included in the analysis. SARS-CoV-2 was the most frequent viral infection (48%), followed by influenza A or B (5%), and a combination of SARS-CoV-2 and influenza (9%). RSV was not detected in any specimen. Several participants carried two or three viruses simultaneously. Throat swabs were significantly more sensitive for detecting SARS- CoV-2 (79%) and influenza (64%) than samples from other sites. In contrast, saliva had the lowest sensitivity for SARS- CoV-2 (43 % ) and was unsuitable for detecting influenza. The sensitivity for SARS- CoV-2 (88 % ) and influenza (100 % ) improved when results from throat and nasal swabs were combined. Throat swabs were more sensitive than nasopharyngeal swabs and saliva for molecular detection of SARS-CoV-2 and influenza. A combined throat and nasal swab is highly recommended to increase test sensitivity in patients presenting with upper respiratory infection symptoms. IMPORTANCE: Upper respiratory infections are the most common condition in primary care. Therefore, their early diagnosis is essential to control infectious disease transmission within the community. Here, we show that throat swabs were more sensitive than nasopharyngeal swabs and saliva for detecting severe acute respiratory syndrome coronavirus 2. Furthermore, throat and nasal swabs were more effective in detecting influenza compared to nasopharyngeal swabs. CLINICAL TRIALS: Registered at ClinicalTrials.gov NCT05765838.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.